• 1
    Morales A, Buvat J, Gooren LJ, Guay AT, Kaufman JM, Kim YC, Tan HM, Torres LO. Endocrine Aspects of Men Sexual Dysfunction. In: Sexual Medicine, Sexual Dysfunctions in Men and Women, 2nd International Consultation on Sexual Dysfunctions, Paris. TFLue, RBasson, RRosen, FGuliano, SKhoury, FMontorsi, eds. Paris: Health Publications; 2004:34782.
  • 2
    Buvat J, Shabsigh R, Guay A, Gooren L, Torres LO, Meuleman E. Hormones, Metabolism, Aging, and Men's Health. In Standard practice in Sexual Medicine, HPorst & JBuvat, eds, Malden, Massachusetts, and Oxford, UK: Blackwell Publishing; 2006:22586.
  • 3
    Wang C, Nieschlag E, Swerdloff R, Behre HM, Hellstrom WJ, Gooren LJ, Kaufman JM, Legros JJ, Lunenfeld B, Morales A, Morley JE, Schulman C, Thompson IM, Weidner W, Wu FC. Investigation, treatment and monitoring of late-onset hypogonadism in males: ISA, ISSAM, EAU, EAA and ASA recommendations. Eur J Endocrinol 2008;159:50714.
  • 4
    Morelli A, Corona G, Vignozzi L, Ambrosini S, Filippi S, Forti G, Maggi M. Which patients with sexual dysfunction are suitable for testosterone replacement therapy? J Endocrinol Invest 2007;30:8808.
  • 5
    Corona G, Mannucci E, Petrone L, Giommi R, Mansani R, Fei L, Forti G, Maggi M. Psycho-biological correlates of hypoactive sexual desire in patients with erectile dysfunction. Int J Impot Res 2004;16:27581.
  • 6
    Zitzmann M, Faber S, Nieschlag E. Association of specific symptoms and metabolic risks with serum testosterone in older men. J Clin Endocrinol Metab 2006;91:433543.
  • 7
    Beutel ME, Wiltink J, Hauck EW, Auch D, Behre HM, Brahler E, Weidner W. Correlations between hormones, physical, and affective parameters in aging urologic outpatients. Eur Urol 2005;47:74955.
  • 8
    Carosa E, Martini P, Brandetti F, Di Stasi SM, Lombardo F, Lenzi A, Jannini EA. Type V phosphodiesterase inhibitor treatments for erectile dysfunction increase testosterone levels. Clin Endocrinol (Oxf) 2004;61:3826.
  • 9
    Travison TG, Araujo AB, Morley JE, O'Donnell AB, McKinlay JB. The relationship between libido and testosterone in aging men: Results from the Massachussetts Male Aging Study. J Clin Endocrinol Metab 2006;91:250913.
  • 10
    Corona G, Mannucci E, Ricca V, Lotti F, Boddi V, Bandini E, Balercia G, Forti G, Maggi M. The age-related decline of testosterone is associated with different specific symptoms and signs in patients with sexual dysfunction. Int J Androl 2009 Feb 10. [Epub ahead of print.
  • 11
    Corona G, Jannini EA, Mannucci E, Fisher AD, Lotti F, Petrone L, Balercia G, Bandini E, Chiarini V, Forti G, Maggi M. Different testosterone levels are associated with ejaculatory dysfunction. J Sex Med 2008;5:19918.
  • 12
    Corona G, Mannucci E, Petrone L, Fisher AD, Balercia G, De Scisciolo G, Pizzocaro A, Giommi R, Chiarini V, Forti G, Maggi M. Psychobiological correlates of delayed ejaculation in male patients with sexual dysfunctions. J Androl 2006;27:4538.
  • 13
    Corona G, Mannucci E, Forti G, Maggi M. Hypogonadism, ED, metabolic syndrome and obesity: A pathological link supporting cardiovascular diseases. Int J Androl 2009 Feb 10. (Epub head of print).
  • 14
    Traish AM, Guay AT, Feeley R, Saad F. The Dark Side of Testosterone Deficiency: I. Metabolic Syndrome & Erectile Dysfunction. Journal of Andrology 2009;30:1022.
  • 15
    Traish AM, Saad F, Guay AT. The Dark Side of Testosterone Deficiency: II. Type 2 Diabetes & Insulin Resistance. Journal of Andrology 2009;30:2332.
  • 16
    Corona G, Mannucci E, Forti G, Maggi M. Following the common association between testosterone deficiency and diabetes mellitus, can testosterone be regarded as a new treatment for diabetes? Int J Androl 2009;32:111.
  • 17
    Corona G, Ferruccio N, Morittu S, Forti G, Maggi M. Recognising late-onset hypogonadism: a difficult task for sexual health care. J Men's Health 2009;6:133276.
  • 18
    Corona G, Boddi V, Lotti F, Gacci M, Carini M, De Vita G, Sforza A, Forti G, Mannucci E, Maggi M. The relationship of testosterone to prostatic-specific androgen in men with sexual dysfunction. J Sex Med 2010;7(1 Pt 1):28492. DOI: 10.1111/j. 1743-6109.2009.01549. 2009, in press.
  • 19
    Corona G, Mannucci E, Petrone L, Ricca V, Balercia G, Mansani R, Chiarini V, Giommi R, Forti G, Maggi M. Association of hypogonadism and type II diabetes in men attending an outpatient erectile dysfunction clinic. Int J Impot Res 2006;18:1907.
  • 20
    Corona G, Mannucci E, Petrone L, Balercia G, Paggi F, Fisher AD, Lotti F, Chiarini V, Fedele D, Forti G, Maggi M. NCEP-ATPIII-defined metabolic syndrome, type 2 diabetes mellitus, and prevalence of hypogonadism in male patients with sexual dysfunction. J Sex Med 2007;4(4 Pt 1):103845.
  • 21
    Corona G, Mannucci E, Petrone L, Schulman C, Balercia G, Fisher AD, Chiarini V, Forti G, Maggi M. A comparison of NCEP-ATPIII and IDF metabolic syndrome definitions with relation to metabolic syndrome-associated sexual dysfunction. J Sex Med 2007;4:78996.
  • 22
    Corona G, Mannucci E, Fisher AD, Lotti F, Petrone L, Balercia G, Bandini E, Forti G, Maggi M. Low levels of androgens in men with erectile dysfunction and obesity. J Sex Med 2008;5:245463.
  • 23
    Guay AT, Jacobson J. The relationship between testosterone levels, the metabolic syndrome (by two criteria), and insulin resistance in a population of men with organic erectile dysfunction. J Sex Med 2007;4:104655.
  • 24
    Svartberg J. Epidemiology of testosterone and the metabolic syndrome. Int J Impot Res 2007;19:1248.
  • 25
    Ding EL, Song Y, Malik VS, Liu S. Sex differences of endogenous sex hormones and risk of type 2 diabetes: a systematic review and meta-analysis. JAMA 2006;295:128899.
  • 26
    Laaksonen DE, Niskanen L, Punnonen K, Nyyssonen K, Tuomainen TP, Valkonen VP, Salonen JT. The metabolic syndrome and smoking in relation to hypogonadism in middle-aged men: A prospective cohort study. Journal of Clinical Endocrinology and Metabolism 2005;90:7129.
  • 27
    Derby CA, Zilber S, Brambilla D, Morales KH, McKinlay JB. Body mass index, waist circumference and waist to hip ratio and change in sex steroid hormones: the Massachusetts Male Ageing Study. Clinical Endocrinolology (Oxf) 2006;65:12531.
  • 28
    Rodriguez A, Muller DC, Metter EJ, Maggio M, Harman SM, Blackman MR, Andres R. Aging, androgens, and the metabolic syndrome in a longitudinal study of aging. J Clin Endocrinol Metab 2007;92:356872.
  • 29
    Gündüz MI, Gümüs BH, Sekuri C. Relationship between metabolic syndrome and erectile dysfunction. Asian Journal of Andrology 2004;6:3558.
  • 30
    Bansal TC, Guay AT, Jacobson J, Woods BO, Nesto RW. Incidence of metabolic syndrome and insulin resistance in a population with organic erectile dysfunction. J Sex Med 2005;2:96103.
  • 31
    Esposito K, Giugliano F, Martedì E, Feola G, Marfella R, D’Armiento M, Giugliano D. High proportions of erectile dysfunction in men with the metabolic syndrome. Diabetes Care 2005;28:12013.
  • 32
    Demir T, Demir O, Kefi A, Comlekci A, Yesil S, Esen A. Prevalence of erectile dysfunction in patients with metabolic syndrome. International Journal of Urology 2006;13:3858.
  • 33
    Bal K, Oder M, Sahin AS, Karataş CT, Demir O, Can E, Gümüş BH, Ozer K, Sahin, Esen AA. Prevalence of metabolic syndrome and its association with erectile dysfunction among urologic patients: Metabolic backgrounds of erectile dysfunction. Urology 2007;69:35660.
  • 34
    Paick JS, Yang JH, Kim SW, Ku JH. Severity of erectile dysfunction in married impotent patients: Interrelationship with anthropometry, hormones, metabolic profiles and lifestyle. International Journal of Urology 2007;14:4853.
  • 35
    Corona G, Fagioli G, Mannucci E, Romeo A, Rossi M, Lotti F, Sforza A, Morittu S, Chiarini V, Casella G, Di Pasquale G, Bandini E, Forti G, Maggi M. Penile doppler ultrasound in patients with erectile dysfunction (ED): Role of peak systolic velocity measured in the flaccid state in predicting arteriogenic ED and silent coronary artery disease. J Sex Med 2008 5:262334.
  • 36
    Yeh HC, Wang CJ, Lee YC, Hsiao HL, Wu WJ, Chou YH, Huang CH. Association among metabolic syndrome, testosterone level and severity of erectile dysfunction. Kaohsiung Journal of Medical Sciences 2008;24:2407.
  • 37
    Vermeulen A, Verdonck L, Kaufman JM. A critical evaluation of simple methods for the estimation of free testosterone in serum. J Clin Endocrinol Metab 1999;84:366672.
  • 38
    Filippi S, Vignozzi L, Morelli A, Chavalmane AK, Sarchielli E, Fibbi B, Saad F, Sandner P, Ruggiano P, Vannelli GB, Mannucci E, Maggi M. Testosterone Partially Ameliorates Metabolic Profile and Erectile Responsiveness to PDE5 Inhibitors in an Animal Model of Male Metabolic Syndrome. J Sex Med 2009 Sep 1. [Epub ahead of print] PubMed PMID: 19732305).
  • 39
    Isidori AM, Giannetta E, Greco EA, Gianfrilli D, Bonifacio V, Isidori A, Lenzi A, Fabbri A. Effects of testosterone on body composition, bone metabolism and serum lipid profile in middle-aged men: A meta-analysis. Clinical Endocrinology 2005;63:28093.
  • 40
    Haddad RM, Kennedy CC, Caples SM, Tracz MJ, Boloña ER, Sideras K, Uraga MV, Erwin PJ, Montori VM. Testosterone and cardiovascular risk in men: A systematic review and meta-analysis of randomized placebo-controlled trials. Mayo Clin Proc 2007;82:2939.
  • 41
    Boyanov MA, Boneva Z, Christov VG. Testosterone supplementation in men with type 2 diabetes, visceral obesity and partial androgen deficiency. Aging Male 2003;6:17.
  • 42
    Kapoor D, Goodwin E, Channer KS, Jones TH. Testosterone replacement therapy improves insulin resistance, glycaemic control, visceral adiposity and hypercholesterolaemia in hypogonadal men with type 2 diabetes. European Journal Endocrinology 2006;154:899906.
  • 43
    Kapoor D, Clarke S, Stanworth R, Channer KS, Jones TH. The effect of testosterone replacement therapy on adipocytokines and C-reactive protein in hypogonadal men with type 2 diabetes. European Journal of Endocrinology 2007;156:595602.
  • 44
    Saad F, Gooren LJ, Haider A, Yassin A. A dose-response study of testosterone on sexual dysfunction and features of the metabolic syndrome using testosterone gel and parenteral testosterone undecanoate. J Androl 2008;29:1025.
  • 45
    Bastounis EA, Karayiannakis AJ, Syrigos K, Zbar A, Makri GG, Alexiou D. Sex hormone changes in morbidly obese patients after vertical banded gastroplasty. Eur Surg Res 1998;30:437.
  • 46
    Kaukua J, Pekkarinen T, Sane T, Mustajoki P. Sex hormones and sexual function in obese men losing weight. Obesity Research 2003;11:68994.
  • 47
    Niskanen L, Laaksonen DE, Punnonen K, Mustajoki P, Kaukua J, Rissanen A. Changes in sex hormone-binding globulin and testosterone during weight loss and weight maintenance in abdominally obese men with the metabolic syndrome. Diabetes Obesity and Metabolism 2004;6:20815.
  • 48
    Smilios I, Pilianidis T, Karamouzis M, Parlavantzas A, Tokmakidis SP. Hormonal responses after a strength endurance resistance exercise protocol in young and elderly males. Int J Sports Med 2007;28:4016.
  • 49
    Baker JR, Bemben MG, Anderson MA, Bemben DA. Effects of age on testosterone responses to resistance exercise and musculoskeletal variables in men. J Strength Cond Res 2006;20:87481.
  • 50
    Kraemer WJ, Volek JS, Clark KL, Gordon SE, Puhl SM, Koziris LP, McBride JM, Triplett-McBride NT, Putukian M, Newton RU, Häkkinen K, Bush JA, Sebastianelli WJ. Influence of exercise training on physiological and performance changes with weight loss in men. Med Sci Sports Exerc Med 1999;31:13209.
  • 51
    Daly RM, Dunstan DW, Owen N, Jolley D, Shaw JE, Zimmet PZ. Does high-intensity resistance training maintain bone mass during moderate weight loss in older overweight adults with type 2 diabetes? Osteoporos Int 2005;16:170312.
  • 52
    Wu FCW, Von Eckardstein A. Androgens and coronary artery disease. Endocr Rev 2003;24:183217.
  • 53
    Choi BG, McLaughlin MA. Why men's heart break: Cardiovascular effects of sex steroids. Endocrinol Metab Clin 2007;36:36577.
  • 54
    McGrath KC, McRobb LS, Heather AK. Androgen therapy and atherosclerotic cardiovascular disease. Vascular Health and Risk Management 2008;4:1121.
  • 55
    Stanworth RD, Jones TH. Testosterone in obesity, metabolic syndrome and type 2 diabetes. Front Horm Res 2009;37:7490.
  • 56
    Hak AE, Witteman JC, De Jong FH, Geerlings MI, Hofman A, Pols HA. Low levels of endogenous androgens increase the risk of atherosclerosis in elderly men: The Rotterdam study. J Clin Endocrinol Metab 2002;87:36329.
  • 57
    Tivesten A, Mellström D, Jutberger H, Fagerberg B, Lernfelt B, Orwoll E, Karlsson MK, Ljunggren O, Ohlsson C. Low serum testosterone and high serum estradiol associate with lower extremity peripheral arterial disease in elderly men. The MrOS Study in Sweden. J Am Coll Cardiol 2007;50:10706.
  • 58
    De Pergola G, Pannacciuli N, Ciccone M, et al. Free testosterone plasma levels are negatively associated with the intima-media thickness of the common carotid artery in overweight and obese glucose-tolerant young adult men. Int J Obes Relat Metab Disord 2007;27:8037.
  • 59
    Fukui M, Kitagawa Y, Nakamura N, et al. Association between serum testosterone concentration and carotid atherosclerosis in men with type 2 diabetes. Diabetes Care 2003;26:186973.
  • 60
    Van Den Beld AW, Bots ML, Janssen JA, Pols HA, Lamberts SW, Grobbee DE. Endogenous hormones and carotid atherosclerosis in elderly men. Am J Epidemiol 2003;157:2531.
  • 61
    Vikan T, Johnsen SH, Schirmer H, Njolstad I. Svartberg, Endogenous testosterone and the prospective association with carotid atherosclerosis in men: The Tromso study. J Epidemiol 2009;24:28995.
  • 62
    Corona G, Mannucci E, Lotti F, Fisher AD, Bandini E, Balercia G, Forti G, Maggi M. Pulse pressure, an index of arterial stiffness, is associated with androgen deficiency and impaired penile blood flow in men with ED. J Sex Med 2009;6:28593.
  • 63
    Yaron M, Greenman Y, Rosenfeld JB, Izkhakov E, Limor R, Osher E, Shenkerman G, Tordjman K, Stern N. Effect of testosterone replacement therapy on arterial stiffness in older hypogonadal men. Eur J Endocrinol 2009;160:83946.
  • 64
    Shahani S, Braga-Basaria M, Basaria S. Androgen deprivation therapy in prostate and metabolic risk for metabolic risk and atherosclerosis. J Clin Endocrinol Metab 2008;93:20429.
  • 65
    Keating NL, O’Malley AJ, Smith MR. Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer. J Clin Oncol 2006;24:444856.
  • 66
    Basaria S, Muller DC, Carducci MA, Egan J, Dobs AS. Hyperglycemia and insulin resistance in men with prostate carcinoma who receive androgen deprivation therapy. Cancer 2006;106:5818.
  • 67
    Saigal CS, Gore JL, Krupski TL, Hanley J, Schonlau M, Litwin MS. Androgen deprivation therapy increases cardiovascular mortality in men with prostate cancer. Cancer 2007;110:14931500.
  • 68
    D’Amico AV, Denham JW, Crook J, Chen MH, Goldhaber SZ, Lamb DS, Joseph D, Tai KH, Malone S, Ludgate C, Steigler A, Kantoff PW. Influence of androgen suppression therapy for prostate cancer on the frequency and timing of fatal myocardial infarctions. J Clin Oncol 2007;25:24205.
  • 69
    Efstathiou JA, Kyounghwa B, Shipley WU, Hanks GE, Pilepich MV, Sandler HM, Smith MR. Cardiovascular Mortality and Duration of Androgen Deprivation for Locally Advanced Prostate Cancer: Analysis of RTOG 92-02. European Urology 2008;54:81624.
  • 70
    Abbott RD, Launer LJ, Rodriguez BL, Ross GW, Wilson PW, Masaki KH, Strozyk D, Curb JD, Yano K, Popper JS, Petrovitch H. Serum estradiol and risk of stroke in elderly men. Neurology 2007;68:5638.
  • 71
    Arnlov J, Pencina MJ, Amin S, et al. Endogenous sex hormones and cardiovascular disease incidence in men. Ann Intern Med 2006;145:17684.
  • 72
    Barrett-Connor E, Khaw KT. Endogenous sex hormones and cardiovascular disease in men. A prospective population-based study. Circulation 1988;3:53945.
  • 73
    Cauley JA, Gutai JP, Kuller LH, Dai WS. Usefulness of sex steroid hormone levels in predicting coronary artery disease in men. Am J Cardiol 1987;60:7717.
  • 74
    Contoreggi CS, Blackman MR, Andres R, Muller DC, Lakatta EG, Fleg JL, Harman SM. Plasma levels of estradiol, testosterone, and DHEAS do not predict risk of coronary artery disease in men. J Androl 1990;11:46070.
  • 75
    Harman SM, Metter EJ, Tobin JD, Pearson J, Blackman MR. Longitudinal effects of aging on serum total and free testosterone levels in healthy men. Baltimore Longitudinal Study of Aging. J Clin Endocrinol Metab 2001;86:72431.
  • 76
    Hautanen A. Mänttäri M, Manninen V, Tenkanen L, Huttunen JK, Frick MH, Adlercreutz H. Adrenal androgens and testosterone as coronary risk factors in the Helsinki Heart Study. Atherosclerosis 1994;105:72431.
  • 77
    Phillips GB, Yano K, Stemmermann GN. Serum sex hormone levels and myocardial infarction in the Honolulu Heart Program. Pitfalls in prospective studies on sex hormones. J Clin Epidemiol 1988;41:11516.
  • 78
    Yarnell JW, Beswick AD, Sweetnam PM, Riad-Fahmy D. Endogenous sex hormones and ischemic heart disease in men. The Caerphilly prospective study. Arterioscler Thromb 1993;4:51720.
  • 79
    Araujo AB, Kupelian V, Page ST, Handelsman DJ, Bremner WJ, McKinlay JB. Sex steroids and all-cause and cause-specific mortality in men. Arch Intern Med 2007;167:125260.
  • 80
    Maggio M, Lauretani F, Ceda GP, Bandinelli S, Ling SM, Metter EJ, Artoni A, Carassale L, Cazzato A, Ceresini G, Guralnik JM, Basaria S, Valenti G, Ferrucci L. Relationship between low levels of anabolic hormones and 6-year mortality in older men: The aging in the Chianti Area (InCHIANTI) study. Arch Intern Med 2007;167:224954.
  • 81
    Khaw KT, Dowsett M, Folkerd E, Bingham S, Wareham N, Luben R, Welch A, Day N. Endogenous testosterone and mortability due to all causes, cardiovascular disease and cancer in men. Circulation 2007;116:2694701.
  • 82
    Laughlin GA, Barrett-Connor E, Bergstrom J. Low Serum Testosterone and Mortality in Older Men. J Clin Endocrinol Metab 2008;93:6875.
  • 83
    Corona G, Monami M, Boddi V, Cameron-Smith M, Fisher A, De Vita G, Melani C, Balzi D, Sforza A, Forti G, Mannucci E, Maggi M. Low testosterone is associated with an increased risk of MACE lethality in subjects with erectile dysfunction. J Sex Med, in press.
  • 84
    Muller M, Van Den Beld AW, Bots ML, Grobbee DE, Lamberts SW, Van Der Schouw YT. Endogenous sex hormones and progression of carotid atherosclerosis in elderly men. Circulation 2004;109:20749.
  • 85
    Yeap BB, Hyde Z, Almeida OP, NBorman PE, Chubb SA. Lower testosterone levels predict incident stroke and transient ischemic attack in older men. J Clin Endocr Metab 2009;94:23539.
  • 86
    Smith GD, Ben-Shlomo Y, Beswick A, Yarnell J, Lightman S, Elwood P. Cortisol, testosterone, and coronary heart disease: Prospective evidence from the Caerphilly study. Circulation 2005;112:33240.
  • 87
    Morley JE, Charlton E, Patrick P, Kaiser FE, Cadeau P, McCready D, Perry HM III. Validation of a screening questionnaire for androgen deficiency in aging males. Metabolism 2000;49:123942.
  • 88
    Heinemann LAJ, Saad F, Thiele K, Wood-Dauphinee S. The Aging Males’ Symptoms (AMS) rating scale. Cultural and linguistic validation into English. The Aging Male 2001;3:1422.
  • 89
    Smith KW, Feldman HA, McKinlay JB. Construction and field validation of a self-administered screener for testosterone deficiency (hypoganadism) in ageing men. Clin Endocrinol (Oxf) 2000;53:70311.
  • 90
    Morley JE, Perry HM, Kevorkian RT, Patrick P. Comparison of screening questionnaires for the diagnosis of hypogonadism. Maturitas 2006;53:4249.
  • 91
    Corona G, Mannucci E, Petrone L, Balercia G, Fisher AD, Valerio Chiarini, Forti G, Maggi M. ANDROTEST©: A Structured Interview for the Screening of Hypogonadism in Patients with Sexual Dysfunction. J Sex Med 2006;3:70615.
  • 92
    Wang C, Catlin DH, Demers LM, Starcevic B, Swerdloff RS. Measurement of total serum testosterone in adult men: Comparison of current laboratory methods versus liquid chromatography-tandem mass spectrometry. J Clin Endocrinol Metab 2004;89:53443.
  • 93
    Buvat J, Bou Jaoudé G. Significance of hypogonadism in erectile dysfunction. World J Urol 2006;24:65767.
  • 94
    Zitzmann M, Nieschlag E. Androgen receptor gene CAG repeat length and body mass index modulate the safety of long-term intramuscular testosterone undecanoate therapy in hypogonadal men. J Clin Endocrinol Metab 2007;92:384453.
  • 95
    Zitzmann M. The role of the CAG repeat androgen receptor polymorphism in andrology. Front Horm Res 2009;37:5261.
  • 96
    Gooren LJ. Androgen levels and sex functions in testosterone-treated hypogonadal men. Arch Sex Behav 1987;16:46373.
  • 97
    Kelleher S, Conway AJ, Handelsman DJ. Blood testosterone threshold for androgen deficiency symptoms. J Clin Endocrinol Metab 2004;89:38137.
  • 98
    Salmimies P, Kockott G, Pirke KM, Vogt HJ, Schill WB. Effects of Testosterone Replacement on Sexual Behavior in Hypogonadal Men. Arch Sex Behav 1982;11:34553.
  • 99
    Gray PB, Sigh AB, Woodhouse LJ, Storer TW, Casaburi R, Dzekov C, Dzekov J, Sinha-Hikim I, Bhasin S. Dose-dependant effects of testosterone on sexual function, mood, and visuospatial cognition in older men. J Clin Endocrinol Metab 2005;16:3.
  • 100
    Sherlock M, Toogood AA. Aging and the growth hormone/insulin like growth factor-I axis. Pituitary 2007;10:189203.
  • 101
    Hamed EA, Meki MA, Gaafar AAA, Hamed SA. Role of some vasoactive mediators in patients with erectile dysfunction: Their relationship with angiotensin-converting enzyme and growth hormone. Int J Impot Res 2003;15:41825.
  • 102
    Brill KT, Weltman AL, Gentili A, Patrie JT, Fryburg DA, Hanks JB, Urban RJ, Veldhuis JD. Single and combined effects of growth hormone and testosterone administration on measures of body composition, physical performance, mood, sexual function, bone turnover, and muscle gene expression in healthy older men. J Clin Endocrinol Metab 2002;87:564957.
  • 103
    Münzer T, Harman SM, Hees P, Shapiro E, Christmas C, Bellantoni MF, Stevens TE, O’Connor KG, Pabst KM, St Clair C, Sorkin JD, Blackman MR. Effects of GH and/or sex steroid administration on abdominal subcutaneous and visceral fat in healthy aged women and men. J Clin Endocrinol Metab 2001;86:360410.
  • 104
    Giannoulis G, Sonken PH, Umpleby M, Breen L, Pentecost C, Whyte M, McMillan C, Bradley C, Martin F. The effects of growth hormone and/or testosterone in healthy elderly men: A randomized controlled trial. J Clin Endocrinol Metal 2006;91:47784.
  • 105
    Buvat J. Androgen therapy with dehydroepiandrosterone. World J Urol 2003;21:34655.
  • 106
    Williams MRI, Dawood T, Ling S, Dai A, Lew R, Myles K, Funder JW, Sudhir K, Komesaroff PA. Dehydroepiandrosterone increases endothelial cell proliferation in Vitro and improves endothelial function in Vivo by mechanisms independent of androgen and estrogen receptors. J Clin Endocrinol Metab 2004;89:470815.
  • 107
    Baulieu E, Thomas G, Legrain S, Lahou N, Roger M, Debuire B, Faucounau V, Girard L, Hervy M, Latour F, Leaud M, Mokrane A, Pitti-Ferrandi H, Trivalle C, DeLacharriere O, Nouveau S, Rakoto-Arison B, Souberbielle J, Raison J, LeBouc Y, Raynaud A, Girerd X, Forette F. Dehydroepiandrosterone (DHEA), DHEA sulfate, and aging: Contribution of the DHEAge study to a sociobiomedical issue. Proceedings of the National Academy of Sciences of the United States of America 2000;97:427984.
  • 108
    Reiter WJ, Pycha A, Schatzl G, et al. Dehydroepiandrosterone in the treatment of Erectile Dysfunction: A prospective, double-blind, randomized, placebo-controlled study. Urology 1999;53:5904.
  • 109
    Bhasin S, Cunningham GR, Hayes FJ, Matsumoto AM, Snyder PJ, Swerdloff RS, Montori VM. Testosterone therapy in adult men with androgen deficiency syndromes: An Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2006;91:19952010.
  • 110
    Kaufman JM, Vermeulen A. The decline of androgen levels in elderly men and its clinical and therapeutic implications. Endocr Rev 2005;26:83376.
  • 111
    Gray A, Feldman HA, McKinlay JB, Longcope C. Age, disease, and changing sex hormone levels in middle-aged men: Results of the Massachusetts Male Aging Study. J Clin Endocrinol Metab 1991;73:101625.
  • 112
    Stellato RK, Feldman HA, Hamdy O, Horton ES, McKinlay JB. Testosterone, sex hormone-binding globulin, and the development of type 2 diabetes in middle-aged men: Prospective results from the Massachusetts male aging study. Diabetes Care 2000;23:4904.
  • 113
    Mohr BA, Guay AT, O'Donnell AB, McKinlay JB. Normal, bound and nonbound testosterone levels in normally ageing men: results from the Massachusetts Male Ageing Study. Clin Endocrinol (Oxf) 2005;62:6473.
  • 114
    Bolona ER, Uraga MV, Haddad RM, et al. Testosterone use in men with sexual dysfunction: A systematic review and meta-analysis of randomized placebo-controlled trials. Mayo Clin Proc 2007;82:208.
  • 115
    Allan CA, Forbes EA, Strauss BJ, McLachlan RI. Testosterone therapy increases sexual desire in ageing men with low-normal testosterone levels and symptoms of androgen deficiency. Int J Impot Res 2008;20:396401.
  • 116
    Buvat J, Arver S, Behre H, Meuleman E, Moncada I, Martin-Morales A, Chevallier D. A placebo-controlled study of the effects on insulin sensitivity and sexual function of transdermal testosterone gel in hypogonadal men with type II diabetes and/or metabolic syndrome: data from the TIMES 2 study. J Sex Med 2009;6:suppt2,56,PD-033.
  • 117
    Buvat J, Lemaire A, Ratasczyk J. Rôle des hormones dans les dysfonctions sexuelles, l’homosexualité, le transsexualisme et les comportements sexuels déviants: Conséquences diagnostiques et thérapeutiques. Contraception-Fertilité-Sexualité 1996;24:83446.
  • 118
    Traish AM, Guay AT. Are androgens critical for penile erections in humans? Examining the clinical and preclinical evidence. J Sex Med 2006;3:382407.
  • 119
    Isidori AM, Gianetta E, Gianfrilli D, Greco EA, Bonifacio V, Aversa A, Isidori A, Fabbri A, Lenzi A. Effects of testosterone on sexual function in men: Results of a meta-analysis. Clin Endocrinol (Oxf) 2005;63:38194.
  • 120
    Buvat J, Lemaire A. Endocrine screening in 1022 men with erectile dysfunction: Clinical significance and cost-effective strategy. J Urol 1997;158:7647.
  • 121
    Yassin AA, Saad F. Treatment of sexual dysfunction of hypogonadal patients with long-acting testosterone undecanoate (Nebido). World J Urol 2006;24:63944.
  • 122
    Morelli A, Filippi S, Mancina R, Luconi M, Vignozzi L, Marini M, Orlando C, Vannelli GB, Aversa A, Natali A, Forti G, Giorgi M, Jannini EA, Ledda F, Maggi M. Androgens regulate phosphodiesterase type 5 expression and functional activity in corpora cavernosa. Endocrinology 2004;145:225363.
  • 123
    Buvat J, Bou Jaoude G. Combination Therapy With Phosphodiesterase Type V Inhibitors and Testosterone. Current Sexual Health Reports 2008;5:13540.
  • 124
    Kalinchenko SY, Kozlov GI, Gontcharov NP, et al. Oral testosterone undecanoate reverses erectile dysfunction associated with diabetes mellitus in patients failing on sildenafil citrate therapy alone. Aging Male 2003;6:949.
  • 125
    Teloken PE, Ohebshalom M, Mohideen N, et al. Analysis of the impact of androgen deprivation therapy on sildenafil citrate response following radiation therapy for prostate cancer. J Urol 2007;178:25215.
  • 126
    Park K, Ku JH, Kim SW, et al. Risk factors in predicting a poor response to sildenafil citrate in elderly men with erectile dysfunction. BJU Int 2005;95:36670.
  • 127
    Foresta C, Caretta N, Rossato M, Garolla A, Ferlin A. Role of androgens in erectile function. J Urol 2004;171:235862.
  • 128
    Aversa A, Isidori AM, De Martino MU, Caprio M, Fabbrini E, Rocchietti-March M, et al. Androgens and penile erection: evidence for a direct relationship between free testosterone and cavernous vasodilation in men with erectile dysfunction. Clin Endocrinol (Oxf) 2000;53:51722.
  • 129
    Shabsigh R, Kaufman JM, Steidle C, Padma-Nathan H. Randomized study of testosterone gel as adjunctive therapy to sildenafil in hypogonadal men with erectile dysfunction who do not respond to sildenafil alone. J Urol 2004;172:65863.
  • 130
    Buvat J, Maggi M, Porst H, Colson MH, Kaipia A, Martin-Morales A, Eardley I. What is the threshold level of the PDE5 inhibitors’ testosterone dependence in men? A double blind placebo-controlled trial of testosterone gel addition in men with ED non responding to tadalafil 10 mg once a day alone. 24th annual EAU congress Stockholm 17–21 march 2009, abstract 379.
  • 131
    Gooren LJ, Bunck MC. Androgen Replacement Therapy: present and future. Drugs 2004;64:186191.
  • 132
    Zitzmann M, Gooren LJ. Advances in Testosterone Therapy Replacement. Front Horm Res 2008;37:3049.
  • 133
    Meikle AW, Arver S, Dobs AS, Sanders SW, Rajaram L, Mazer NA. Pharmacokinetics and metabolism of a permeation-enhanced testosterone transdermal system in hypogonadal men: influence of application site – a clinical research center study. J Clin Endocrinol Metab 1996;81:183240.
  • 134
    De Ronde W. Hyperandrogenism after transfer of topical testosterone gel: Case report and review of published and unpublished studies. Hum Reprod 2009;24:4258.
  • 135
    Meier C, Liu PY, Ly LP, De Winter-Modzelewski J, Jimenez M, Handelsman DJ, Seibel MJ. Recombinant human chorionic gonadotropin but not dihydrotestosterone alone stimulates osteoblastic collagen synthesis in older men with partial age-related androgen deficiency. J Clin Endocrinol Metab 2004;89:303341.
  • 136
    Kunelius P, Lukkarinen O, Hannuksela ML, Itkonen O, Tapanainen JS. The effects of transdermal diydrotestosterone in the aging male: A prospective, randomized, double blind Study. J Clin Endocrinol Metab 2002;87:146772.
  • 137
    Ly LP, Jimenez M, Zhuang TN, Celermajer DS, Conway AJ, Handelsman DJ. A double-blind, placebo-controlled, randomized clinical trial of transdermal dihydrotestosterone gel on muscular strength, mobility, and quality of life in older men with partial androgen deficiency. J Clin Endocrinol Metab 2001;86:407888.
  • 138
    Filippi S, Luconi M, Granchi S, Vignozzi L, Bettuzzi S, Tozzi P, Ledda F, Forti G, Maggi M. Estrogens, but not androgens, regulate expression and functional activity of oxytocin receptor in rabbit epididymis. Endocrinology 2002;143:427180.
  • 139
    Smith MR. Treatment-related osteoporosis in men with prostate cancer. Clin Cancer Res 2006;12:6315s9s.
  • 140
    Shabsigh A, Kang Y, Shabsigh R, Gonzalez R, Liberson G, Fisch H, Goluboff E. Clomiphene Citrate Effects on Testosterone/Estrogen Ratio in Male Hypogonadism. J Sex Med 2005;2:71621.
  • 141
    Guay AT, Jacobson J, Perez JB, Hodge MB, Velasquez E. Clomiphene increases free testosterone levels in men with both secondary hypogonadism and erectile dysfunction: who does and does not benefit? Int J Impot Res 2003;15:15665.
  • 142
    Guay AT, Bansal S, Heatley GJ. Effect of raising endogenous testosterone levels in impotent men with secondary hypogonadism: double blind placebo-controlled trial with clomiphene citrate. J Clin Endocrinol Metab 1995;80:354652.
  • 143
    Ribeiro RS, Abucham J. Recovery of persistent hypogonadism by clomiphene in males with prolactinomas under dopamine agonist treatment. Eur J Endocrinol 2009;161:1639.
  • 144
    Stergiopoulos K, Brennan JJ, Mathews R, Setaro JF, Kort S. Anabolic steroids, acute myocardial infarction and polycythemia: A case report and review of the literature. Vasc Health Risk Manag 2008;4:147580.
  • 145
    Handelsman DJ. Testosterone: use, misuse and abuse. Med J Aust 2006;185:4369.
  • 146
    Parkinson AB, Evans NA. Anabolic androgenic steroids: a survey of 500 users. Med Sci Sports Exerc 2006;38:64451.
  • 147
    Dhar R, Stout CW, Link MS, Homoud MK, Weinstock J, Estes NA 3rd. Cardiovascular toxicities of performance-enhancing substances in sports. Mayo Clin Proc 2005;80:130715.
  • 148
    Santamarina RD, Besocke AG, Romano LM, Ioli PL, Gonorazky SE. Ischemic stroke related to anabolic abuse. Clin Neuropharmacol 2008;31:805.
  • 149
    Parssinen M, Kujala U, Vartiainen E, Sarna S, Seppala T. Increased premature mortality of competitive powerlifters suspected to have used anabolic agents. Int J Sports Med 2000;21:2257.
  • 150
    Belhani D, Fanton L, Vaillant F, Descotes J, Manati W, Tabib A, Bui-Xuan B, Timour Q. Cardiac lesions induced by testosterone: protective effects of dexrazoxane and trimetazidine. Cardiovasc Toxicol 2009;9:649.
  • 151
    Krauss DJ, Taub HA, Lantinga LJ, Dunsky MH, Kelly CM. Risks of blood volume changes in hypogonadal men treated with testosterone enanthate for erectile impotence. J Urol 1991;146:156670.
  • 152
    Lane HA, Grace F, Smith JC, Morris K, Cockcroft J, Scanlon MF, Davies JS. Impaired vasoreactivity in bodybuilders using androgenic anabolic steroids. Eur J Clin Invest 2006;36:4838.
  • 153
    O’Connor DB, Archer J, Wu FC. Effects of testosterone on mood, aggression, and sexual behavior in young men: A double-blind, placebo-controlled, cross-over study. J Clin Endocrinol Metab 2004;89:283745.
  • 154
    Talih F, Fattal O, Malone D Jr. Anabolic steroid abuse: psychiatric and physical costs. Cleve Clin J Med 2007;74:3414, 346, 349–52.
  • 155
    D’Amico AV, Renshaw AA, Loffredo M, Chen MH. Duration of testosterone suppression and the risk of death from prostate cancer in men treated using radiation and 6 months of hormone therapy. Cancer 2007;110:17238.
  • 156
    Monath JR, McCullough DL, Hart LJ, Jarow JP. Physiologic variations of serum testosterone within the normal range do not affect serum prostate-specific antigen Urology 1995;46:5861.
  • 157
    Liu CC, Huang SP, Li WM, et al. Relationship between serum testosterone and measures of benign prostatic hyperplasia in aging men. Urology 2007;70:67780.
  • 158
    Behre HM, Bohmeyer J, Nieschlag E. Prostate volume in testosterone-treated and untreated hypogonadal men in comparison to age-matched normal controls. Clin Endocrinology 1994;40:3419.
  • 159
    Jin B, Conway AJ, Handelsman DJ. Effects of androgen deficiency and replacement on prostate zonal volumes. Clin Endocrinol 2001;54:43745.
  • 160
    Marberger M, Roehrborn CG, Marks LS, et al. Relationship among serum testosterone, sexual function, and response to treatment in men receiving dutasteride for benign prostatic hyperplasia J Clin Endocrinol Metab 2006;91:13238.
  • 161
    Roddam AW, Allen NE, Appleby P, Key TJ. Endogenous Hormones Prostate Cancer Collaborative Group, Endogenous sex hormones and prostate cancer: A collaborative analysis of 18 prospective studies. J Nat Cancer Inst 2008;100:17083.
  • 162
    Morgentaler A, Rhoden EL. Prevalence of prostate cancer among hypogonadal men with prostate-specific antigen of 4.0 ng/ml or less. Urology 2006;68:12637.
  • 163
    Morgentaler A. Testosterone deficiency and prostate cancer: Emerging recognition of an important and troubling relationship. Eur Urol 2007;52:6235.
  • 164
    Morgentaler A, Traish AM. Shifting the Paradigm of Testosterone and Prostate Cancer: The Saturation Model and the Limits of Androgen-Dependent Growth. Eur Urol 2009;55:31020.
  • 165
    Calof OM, Singh AB, Lee ML, Kenny AM, Urban RJ, Tenover JL, Bhasin S. Adverse events associated with testosterone replacement in middle-aged and older men: A meta-analysis of randomized, placebo-controlled trials. J Gerontol A Biol Sci Med Sci 2005;60:14517.
  • 166
    Grinspoon S, Corcoran C, Parlman K, Costello M, Rosenthal D, Anderson E, Stanley T, Schoenfeld D, Burrows B, Hayden D, Basgoz N, Klibanski A. Effects of testosterone and progressive resistance training in eugonadal men with AIDS wasting. A randomized, controlled trial. Ann Intern Med 2000;133:34855.
  • 167
    Ferrando A, Sheffield M, Yeckel C, Gilkison C, Jiang J, Achacosa A, Lieberman S, Tipton K, Wolf R, Urban RJ. Testosterone administration in older men improves muscle function: molecular physiological mechanisms. J Phys Endocrinol 2002;282:6017.
  • 168
    Snyder PJ, Peachey H, Hannoush P, Berline JA, Loh L, Lenrow DA, Holmes JH, Dlewati A, Santanna J, Rosen CJ, Strom BL. Effect of testosterone treatment on body composition and muscle strength in men over 65 years of age. J Clin Endocrinol Metab 1999;84:264753.
  • 169
    Crawford BA, Liu PY, Kean MT, Bleasel JF, Handelsman DJ. Randomized placebo-controlled trial of androgen effects on muscle and bone in men requiring long-term systematic glucocorticoid treatment. J Clin Endocrinol Metab 2003;88:316776.
  • 170
    Tan RS, Pu SJ. A pilot study on the effects of testosterone in hypogonadal aging male patients with Alzheimer's disease. Aging Male 2003;6:137.
  • 171
    Sih R, Morley JE, Kaiser FE, et al. Testosterone replacement in older hypogonadal men: A 12 month randomized controlled trial. J Clin Endocrinol Metab 1997;82:16617.
  • 172
    Emmeloot-Vonck M, Verhaar HJJ, Nakhai-Pour HR, Aleman A, Lock TMTW, Bosch JLH, Grobbee DE, Van Der Schouw YT. Effet of testosterone supplementation on functional mobility, cognition, and other parameters in older men. JAMA 2008;299:63443.
  • 173
    Legros JJ, Meuleman E, Ilbers J, Geurts P, Kaspers M, Bouloux P. Oral testosterone replacement in symtomatic late-onset hypogonadism: Effects on rating scales and general safety in a randomized, placebo-controlled study. Eur J Endocrinol 2009;160:82131.
  • 174
    Steidle C, Schwartz S, Jacoby K, Sebree T, Smith T, Bachand R. AA2500 testosterone gel normalizes androgen levels in aging males with improvements in body composition and sexual function. J Clin Endocrinol Metab 2003;88:267381.
  • 175
    Cavallini G, Caracciolo S, Vitali F, Mondenini F, Biagiotti G. Carnitine versus androgen administration in the treatment of sexual dysfunction, depressed mood, and fatigue associated with male aging. Urology 2004;63:6416.
  • 176
    Tenover JS. Effects of testosterone supplementation in the aging male. J Clin Endocrinol Metab 1992;75:10928.
  • 177
    Nair S, Rizza RA, O’Brien P, Dhatariya K, Short KR, Nehra A, Vittone JL, Klee GG, Basu A, Basu R, Cobelli C, Toffolo G, Dalla Man C, Tindall DJ, Melton LJ 3rd, Smith GE, Khosla S, Jensen MD. DHEA in elderly women and DHEA or testosterone in elderly men. N Engl J Med 2006;355:164759.
  • 178
    Amory JK, Watts NB, Easley KA, Sutton PR, Anawalt BD, Matsumoto AM, Bremner WJ, Tenover JL. Exogenous testosterone or testosterone with finasteride increases bone mineral density in older men with low serum testosterone. J Clin Endocrinol Metab 2004;89:50310.
  • 179
    Allan CA, Strauss BJG, Burger HG, Forbes EA, McLachlan RI. Testosterone therapy prevents ain in visceral adipose tissue and loss of skeletal muscle in non-obese aging men. J Clin End 2007;10:121091.
  • 180
    Kenny AM, Prestwood KM, Gruman CA, Marcello KM, Raisz LG. Effects of transdermal testosterone on bone and muscle in order men with low bioavailable testosterone levels. J Gerontol A Biol Sci Med Sci 2001;56:M266M272.
  • 181
    Wittert GA, Chapman IM, Haren MT, Mackintosh S, Coates P, Morley JE. Oral testosterone supplementation increases muscle and decreases fat mass in healthy elderly males with low-normal gonadal status. J Gerontol A Biol Sci Med Sci 2003;58:61825.
  • 182
    Marks LS, Mazer NA, Mostaghel E, Hess DL, Dorey FJ, Epstein JI, Veltri RW, Makarov DV, Partin AW, Bostwick DG, Macairan ML, Nelson PS. Effect of testosterone replacement therapy on prostate tissue in men with late-onset hypogonadism: a randomized controlled trial. JAMA 2006;296:235161.
  • 183
    Bhasin S, Storer TW, Asbel-Sethi N, Kilbourne A, Hays R, Sinha-Hikim I, et al. Effects of testosterone replacement with a nongenital, transdermal system, Androderm, in human immunodeficiency virus-infected men with low testosterone levels. J Clin Endocrinol Metab 1998;83:315562.
  • 184
    Casaburi R, Bhasin S, Cosentino L, Porszasz J, Somfay A, Lewis MI, Fournier M, Storer TW. Effects of testosterone and resistance training in men with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2004;170:8708.
  • 185
    Okun MS, Fernandez HH, Rodriguez RL, Romrell J, Suelter M, Munson S, et al. Testosterone therapy in men with Parkinson disease: Results of the TEST-PD Study. Arch Neurol 2006;63:72935.
  • 186
    Shabsigh R, Crawford ED, Nehra A, Slawin KM. Testosterone therapy in hypogonadal men and potential prostate cancer risk: A systematic review. Int J Impot Res 2009;21:923.
  • 187
    Kaufman JM, Graydon J. Androgen Replacement after curative radical prostatectomy for prostate cancer in hypogonadal men. J Urol 2004;172:9202.
  • 188
    Agarwal PK, Oefelein MG. Testosterone Replacement Therapy after primary treatment for prostate cancer. J Urol 2005;173:5336.
  • 189
    Mulhall J, Goldenberg L, Narus J, Gotto G, Tal R, Nabulsi O. Outcomes of testosterone supplementation in hypogonadal men following radical prostatectomy. J Urol 2008;179(supp 4):426.
  • 190
    Khera M, Grober ED, Najari B, Colen JS, Mohamed O, Lamb DJ, Lipshultz LI. Testosterone replacement therapy following radical prostatectomy. J Sex Med 2009;6:116570.
  • 191
    Khera M, Mohamed O, Colen J, Lipshultz L. Early Testosterone usage for erectile preservation in men following radical prostatectomy. 2008; Poster 90 presented at Sexual Medicine Society of North America, Toronto.
  • 192
    Carrion RE, Lockhart JL, Salup R, Hall MK, Arison CN, Davila HH. Analysis of the PSA response after testosterone supplementation in patients who have previously received management for their localized prostate cancer. J Urol 2008;179(suppl 4):428.
  • 193
    Sarosdy MF. Testosterone Replacement for Hypogonadism AfterTreatment of Early Prostate Cancer with Brachytherapy. Cancer 2007;109:53641.
  • 194
    Morales A, Black AM, Emerson LE. Testosterone Administration to Men with Testosterone Deficiency Syndrome (TDS) after Extenal Beam Radiotherapy for Localized Prostate Cancer. BJU Int 2008;103:624.
  • 195
    Morgentaler A, Bennett R, Mohamed O, Chan R, Keera M, Lipshultz L. Testosterone Therapy in Men with Untreated Prostate Cancer on Active Surveillance. 2008; Poster presented at Sexual Medicine Society of North America meeting in Toronto.
  • 196
    Rhoden EL, Morgentaler A. Testosterone Replacement Therapy in Hypogonadal Men at High Risk For Prostate Cancer: Results of 1 Year of Treatment in Men with Prostatic Intraepithelial Neoplasia. J Urol 2003;170:234851.
  • 197
    Thomas SR, Evans PJ, Holland PA, Biswas M. Invasive breast cancer after initiation of testosterone replacement therapy in a man–a warning to endocrinologists. Endocr Pract 2008;14:2013.
  • 198
    Medras A, Filus A, Jozkow P, Winowski J, Sicinska-Wermer T. Breast cancer and long-term hormonal treatment of male hypogonadism. Breast cancer Res treat 2006;96:2635.
  • 199
    Tan RS, Salazar JA. Risks of testosterone replacement therapy in ageing men. Expert Opin Drug Saf 2004;3:599606.
  • 200
    Zitzmann M, Nieschlag E. Androgens and erythropoiesis. In Testosterone: Action, Deficiency, Substitution, E Nieschlag et HMBehre eds, UK: Cambridge University Press; 2004:28396.
  • 201
    Vannucchi AM. Insights into the pathogenesis and management of thrombosis in polycythemia vera and essential thrombocythemia. Intern Emerg Med 2009 Sep 30. [Epub ahead of print.
  • 202
    Hanafy HM. Testosterone therapy and obstructive sleep apnea: Is there a real connection? J Sex Med 2007;4:12416.
  • 203
    Toot J, Jenkins C, Dunphy G, Boehme S, Hart M, Milsted A, Turner M, Ely D. Testosterone influences renal electrolyte excretion in SHR/y and WKY males. BMC Physiol 2008;26:85.
  • 204
    Johannsson G, Gibney J, Wolthers T, Leung KC, Ho KK. Independent and combined effects of testosterone and growth hormone on extracellular water in hypopituitary men. J Clin Endocrinol Metab 2005;90:398994.
  • 205
    Lundh B, Gardner FH. The effect of testosterone in pharmacological doses on plasma volume and on some serum proteins in patients with sickle cell anemia and in sexually impotent men. Scand J Lab Invest 1971;28:7278.
  • 206
    Kim YC, Buvat J, Carson CC, Gooren LJ, Jarow J, Rajfer J, Vermeulen A. Endocrine and metabolic aspects including treatment. In Erectile Dysfunction. Proceedings of the 1st International Consultation on Erectile Dysfunction, Paris, July 1999, AJardin, GWagner, SKhoury, FGiuliano, HPadma-Nathan, RRosen Eds, Paris: Health Publications Ltd; 2000:20740.
  • 207
    Burger HG, De Kretser DM, Hudson B, Wilson JD. Effects of preceding androgen therapy on testicular response to human pituitary gonadotropin in hypogonadotropic hypogonadism: A study of three patients. Fertil Steril 1981;1:648.
  • 208
    Raivio T, Falardeau J, Dwyer A, Quinton R, Hayes FJ, Hughes VA, Cole LW, Pearce SH, Lee H, Boepple P, Crowley WF Jr, Pitteloud N. Reversal of idiopathic hypogonadotropic hypogonadism. N Engl J Med 2007,357:86373.
  • 209
    Liu PY, Baker HW, Jayadev V, Zacharin M, Conway AJ, Handelsman DJ. Induction of spermatogenesis and fertility during gonadotropin treatment of gonadotropin-deficient infertile men: Predictors of fertility outcome. J Clin Endocrinol Metab 2009;94:8018.
  • 210
    Pugh PJ, Jones TH, Channer KS. Acute haemodynamic effects of testosterone in men with chronic heart failure. Eur Heart J 2003;24:90915.
  • 211
    Webb CM, Adamson DL, DeZeigler D, Collins P. Effect of acute testosterone on myocardial ischemia in men with coronary artery disease. Am J Cardiol 1999;83:4379.
  • 212
    Rosano GMC, Leonardo F, Pagnotta P, et al. Acute anti-ischemic effect of testosterone in men with coronary artery disease. Circulation 1999;99:166670.
  • 213
    Jaffe MD. Effect of testosterone on post-exercise ST segment depression. Br Heart J 1977;39:121722.
  • 214
    Malkin CJ, Pugh PJ, Morris PD, Kerry KE, Jones RD, Jones TH, Channer KS. Testosterone replacement in hypogonadal men with angina improves ischemic threshold and quality of life. Heart 2004;90:8716.
  • 215
    Pugh PJ, Jones RD, West JN, et al. Testosterone treatment for men with chronic heart failure. Heart 2004;90:4467.
  • 216
    Malkin CJ, Pugh PJ, West JN, et al. Testosterone therapy in men with moderate severity heart failure: a double-blind randomized placebo controlled trial. Eur Heart J 2006;27:5764.
  • 217
    Caminiti G, Volterrani M, Iellamo F, Marazzi G, Massaro R, Miceli M, Mammi C, Piepoli M, Fini M Rosano G. Effect of long-acting testosterone treatment on functional exercise capacity, skeletal muscle, performance, insulin resistance, and baroreflex sensitivity in elderly patients with chronic heart failure: A double-blind placebo-controlled, randomized study. J Am Coll Cardiol 2009;54:91927.
  • 218
    Coviello AD, Kaplan B, Lakshman KM, Chen T, Singh AB, Bhasin S. Effects of graded doses of testoterone on erythropoiesis in healthy young and older men. J Clin Endocrinol Metab 2008;93:9149.
  • 219
    Christiansen K. Behavioural correlates of testosterone. In Testosterone: Action, Deficiency, Substitution, E Nieschlag et HMBehre ed, UK: Cambridge University Press; 2004:12572.
  • 220
    Buvat J, Boujaoude G. Testosterone replacement therapy in the ageing man. J Men's Health & Gender 2005;2:39699.
  • 221
    Shores MM, Kivlahan DR, Sadak TI, Li EJ, Matsumoto AM. A randomized, double-blind, placebo-controlled study of testosterone treatment in hypogonadal older men with subthreshold depression (dysthymia or minor depression). J Clin Psychiatry 2009;70:100916.
  • 222
    Seidman SN, Orr G, Raviv G, Levi R, Roose SP, Kravitz E, Amiaz R, Weiser M. Effects of testosterone replacement in middle-aged men with dysthymia: A randomized, placebo-controlled clinical trial. J Clin Psychopharmacol 2009;29:21621.
  • 223
    Corona G, Mannucci E, Fisher AD, Lotti F, Ricca V, Balercia G, Petrone L, Forti G, Maggi M. Effect of hyperprolactinemia in male patients consulting for sexual dysfunction. J Sex Med 2007;4:148593.
  • 224
    Buvat J. Hyperprolactinemia and sexual function in men: A short review. Int J Impot Res 2003;15:3737.
  • 225
    Johri AM, Heaton JPW, Morales A. Severe erectile dysfunction is a marker for hyperprolactinemia. Int J Impot Res 2001;13:17682.
  • 226
    De Rosa M, Zarrilli S, Di Sarno A, et al. Hyperprolactinemia in men. Endocrine 2003;20:7582.
  • 227
    Muldoon MF, Mackey RH, Korytkowski MT, Flory JD, Pollock BG, Manuck SB. The metabolic syndrome is associated with reduced central serotoninergic responsivity in healthy community volunteers. J Clin Endocrinol Metab 2006;91:71821.
  • 228
    Corona G, Mannucci E, Jannini EA Lotti F, Ricca V, M Monami M, Boddi V, Bandini E, Balercia G, Forti G, Maggi M. Hypoprolactinemia: A new clinical syndrome in patients with sexual dysfunction. J Sex Med 2009;6:145766.
  • 229
    Corona G, Petrone L, Mannucci E, Jannini EA, Mansani R, Magini A, Giommi R, Forti G, Maggi M. Psycho-biological correlates of rapid ejaculation in patients attending an andrologic unit for sexual dysfunctions. Eur Urol 2004;46:61522.
  • 230
    Carani C, Isidori AM, Granata A, Carosa E, Maggi M, Lenzi A, Jannini EA. Multicenter study on the prevalence of sexual symptoms in male hypo- and hyperthyroid patients. J Clin Endocrinol Metab 2005;90:64729.
  • 231
    Cihan A, Demir O, Demir T, Aslan G, Comlekci A, Esen A. The relationship between premature ejaculation and hyperthyroidism. J Urol 2009;181:127380.
  • 232
    Waldinger DH. Thyroid stimulation hormone assessments in a Dutch cohort of 620 men with premature ejaculation without Erectile Dysfunction. J Sex Med 2005;2:86570.
  • 233
    Krassas GE, Tzimalos K, Papadopoulos F, Pontikides N, Perros P. Erectile dysfunction in patients with hyper-and hypothyroidism: how common and should we treat? J Clin Endocrino Metab 2008;93:18159.